Breast Cancer clinical trials
Showing 351–400 of 1,067 active trials. Describe your situation to see which ones you may be eligible for.
- XTX301 in Patients With Advanced Solid Tumors
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study of DM001 in Patients With Advanced Solid Tumors
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
- Study of AVZO-021 in Patients With Advanced Solid Tumors
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
- A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- Study of XB010 in Subjects With Solid Tumors
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- IDOV-Immune for Advanced Solid Tumors
- Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.